180
Participants
Start Date
October 12, 2016
Primary Completion Date
October 18, 2018
Study Completion Date
June 7, 2022
Tremelimumab
Durvalumab
Best Supportive Care
Tom Baker Cancer Centre, Calgary
BCCA - Vancouver Cancer Centre, Vancouver
The Moncton Hospital, Moncton
Dr. H. Bliss Murphy Cancer Centre, St. John's
QEII Health Sciences Centre, Halifax
Royal Victoria Regional Health Centre, Barrie
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Cancer Centre of Southeastern Ontario at Kingston, Kingston
London Regional Cancer Program, London
Ottawa Hospital Research Institute, Ottawa
Algoma District Cancer Program, Sault Ste. Marie
Odette Cancer Centre, Toronto
University Health Network, Toronto
Windsor Regional Cancer Centre, Windsor
Hopital Charles LeMoyne, Greenfield Park
Hopital de la Cite-de-la-Sante, Laval
L'Hotel-Dieu de Levis, Lévis
CHUM - Hopital Notre-Dame, Montreal
The Jewish General Hospital, Montreal
Centre Integre Universitaire De Sante Et De Services, Montreal
CHUQ-Pavillon Hotel-Dieu de Quebec, Québec
Centre hospitalier universitaire de Sherbrooke, Sherbrooke
Centre hospitalier regional de Trois-Rivieres, Trois-Rivières
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
Collaborators (1)
AstraZeneca
INDUSTRY
Canadian Cancer Trials Group
NETWORK